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Abstract. We investigate the expression and localization of the tumor suppressor protein pVHL as well as the oncoprotein Aurora
A kinase in kidney cancer. Both Aurora A kinase and pVHL protein status were evaluated using immunohistochemistry. The
Aurora A expression is correlated with the Fuhrman grade and the TNM stage, while the pVHL expression is correlated with the
capsule rupture and the TNM stage. Aurora A kinase expression increases in malignant tissue comparing to the non-malignant
one. And there is a decrease in pVHL expression from the adjacent healthy tissues to the tumor‘s ones. The two kinds of
opposite tumor proﬁles display signiﬁcant distribution difference according to TNM stages. It could be proposed that the absence
of Aurora A protein associated with a strong expression of pVHL in clear cells kidney carcinoma are of good prognosis for the
disease.
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1. Introduction
Renal cell carcinoma (RCC) represents 2–3% of all
adults’ malignant diseases. It is the most lethal form
of urological cancer: local signs and symptoms when
occurring appear at an advanced stage of the tumor and
have negative prognostic implications [1]. Generally
this disease is asymptomatic and 74% of renal tumors
are discovered incidentally during an ultrasound or an
abdominal scan requested for something else.
This cancer has a poor prognosiswith a rate of 5 years
survival around 15% [2], because the discovery is often
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at late phase or evenmetastatic phase (20% to 30%) [3].
The high rate of mortality is due not only to the lack
of early warning signs and symptoms, but also to the
lack of effective treatments for patients at a late stage
cancer. The affected people are often aged between 50
and 70 years old. This cancer is rare in children and
young adults [4].
There are several histological subtypes of RCC in-
cluding clear cell, papillary, chromophobe, and onco-
cytoma variants. But the clear cell Renal Cell Carci-
noma (ccRCC) constitutes the most common and ag-
gressive subtype [1]. Despite an increased detection of
small kidney masses with cross-sectional imaging and
subsequent removal with surgery, mortality has not de-
creased. So we need to ﬁnd more tools to improve un-
derstanding and management of this disease. The abro-
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gation of the cell cycle mitotic spindle checkpoint has
been involved in the progression of RCC [5,33].
Aurora-A is a crucial protein in cell division and
many aberrations are assigned to its dysregulation such
as genomic instability, abnormal duplication of the cen-
trosomes and cell transformation. Besides, Aurora A
could function as an oncogene through the abnormal
regulation of centrosome function and this protein is
designated as an essential actor in aneuploidy. Given
its important role in the process of cell cycle, its over-
expression in several cancers that affect: breast [6],
colon [7], esophagus [8], ovary [9] has been reported.
The expression of this protein was also studied in the
kidney cancer [10–12]. Aurora A is a cell cycle proto-
oncogenic serine/threonine kinase, which orchestrates
the proper running of mitosis. It controls the cell en-
try into mitosis [13], the maturation and separation of
centrosomes [14] and the assembly and stability of the
mitotic spindle [13]. It participates also in cytokine-
sis [15]. This centrosomal protein plays a key role in
regulating the cell cycle via its interactionwith p53 pro-
tein, which is a transcription factor and a well-known
tumor suppressor, thus, inducing cell cycle arrest or
apoptosis of the cell when DNA is damaged [16,17].
Finally, at the end of mitosis Aurora A is ubiquiti-
nated and therefore recognized by the 26S proteasome
and degraded through the ubiquitin-proteasome path-
way APC (Anaphase-Promoting Complex). Aurora A
kinase is induced by inactivation of pVHL, a tumor
suppressor protein [18].
Inactivation of the Von Hippel Lindau (VHL) tumor
suppressor gene [19,20] is an early, causal event in the
development of clear cell renal cell carcinomas and is
common in both hereditary and nonhereditary forms.
VHL is the main inactivated gene in ccRCC, with mu-
tations detected in 40–80%of ccRCC patients [21–25].
The pVHL protein has several functions, the best
documented of these functions relates to its role as the
substrate-recognition component of multisubunit ubiq-
uitin ligase complex that also contains elongin B, elon-
gin C, cullin 2, and rbx1 [26]. This E3 ligase is in-
volved in the ubiquitin proteasome pathway to degrade
the endogenous proteins: the major proteolytic system
in the eukaryotic cell. This tumor suppressor protein
controls also the cell cycle exit [27,28] participates in
the assembly and stability of the mitotic spindle [29,
30] ﬁbronectin binding, and extracellular matrix as-
sembly [26] and it is involved in the activity of centro-
somes [31].
The pVHL protein plays a role in chromosome sta-
bility [27] and its absence increases aneuploidy. More-
over it’s involved in the stabilization of the p53 protein,
pVHL directly associates and positively regulates the
tumor suppressor p53 by inhibiting Mdm2-mediated
ubiquitination, Thus pVHL appears to play a crucial
role in tumor suppression by participating actively as
a component of p53 transactivation complex during
DNA damage response, and therefore playing an im-
portant role in cell cycle regulation [27] and regulating
the tumor growth and cytokinesis [32,33].
The protein pVHL is present in the cell under three
isoforms as following: The isoform 1contains exons 1,
2 and 3, it encloses 213 amino acid (AA), has as molec-
ular weight of 30 kDa VHL30 [34] and resides mainly
in the cytoplasm [30]; the isoform 2 contains only exon
1 and 3 corresponding to a protein with 173 AA and a
molecular weight of about 24 KDa; The isoform 3 con-
tains 161 AA with a size of 19 kD, it was formed as a
result of internal translational initiation at an in-frame
start codon (ATG) at codon 54 [35]. VHL19 resides
primarily in the nucleus [30].
The expression status of tumor suppressor pVHL has
been studied in several cancers including ovarian and
uterine cancer ones [45], the colorectal cancer and liver
metastases [36], as well as in the chondrosarcoma [37].
The expression of this protein was also studied in the
kidney [38–41].
Recent studies showed a speciﬁc interaction between
the oncoprotein Aurora A and the tumor suppressor
protein pVHL. These studies included three parts and
started with a study in bioinformatics where the inter-
action ‘in silico’ was predicted with strong probability,
and then an ‘in vitro’ test using a recombinant protein
was done and conﬁrmed this interaction. Finally an ‘in
vivo’ study with endogenous proteins on cell cultures
comes to consolidate this hypothesis [47,48].
In the present paper, we investigate the expression of
Aurora A kinase and pVHL protein in kidney tumors
of CCRCC subtype according to clinical and anato-
mopathological statuses.
2. Material and methods
2.1. Clinical tissue sample
79 archival parafﬁn-embedded tumor sections were
collected from the Pathology department in Charles
Nicolle Hospital-Tunis. They were obtained from pa-
tients who underwent surgery with pathologically con-
ﬁrmed kidney cancer: clear renal cell carcinoma, ad-
mitted to the Department of Urology between 2001 and
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Table 1
Patient characteristics (n = 79)
Characteristic Number of patients (%)
Age (years)
Median 60
Range 36–87
Sexe
Male 42
Female 37
Tumor Size
 70 MM 44
> 70 MM 34
Unknown 1
Partial or complet nephrectomy
Partial 9
Complete 69
Unknown 1
Right or left kidney
Right 32
Left 43
Unknown 4
Renal capsule rupture
Yes 20
No 57
Unknown 2
Fuhrman Grade
I 27
II 35
III 14
IV 3
TNM stage
T1 37
T2 20
T3 20
Unknown 2
2010. The following clinical data were collected: age,
gender, histological subtype, Fuhrman grade, tumor
size, status of the renal capsule and the TNM classi-
ﬁcation stage. The patients’ characteristics are shown
in Table 1. The study protocol was approved by the
hospital head of the histopathology department.
2.2. Antibodies
For Aurora A protein detection we used a mouse
monoclonal antibody (clone 35c1, Sigma) which was
developed against the non-catalytic N-terminal domain
of the kinase. This clone was tested at the UMR6061 in
the Institute of Genetics and Development of Rennes,
France [42]. For pVHL protein revealing we used a
mouse monoclonal anti-Von Hippel Lindau protein
(3F391/Ig33) from Novus Biologicals, Inc.
2.3. Immunohistochemical staining
Sections of thick 3 µm were prepared for each case
and stained with Hematoxylin eosin (H&E) intended
for histological examination.
We proceeded to the review of slides and to their
classiﬁcation before we begin our experimentation on
tumors initially classiﬁed as clear cell carcinomas ac-
cording to ancient criteria. In fact new identities: renal
carcinoma associated with a translocation MITF/TFE,
clear cell papillary carcinoma, and carcinoma associ-
ated with polycystic disease have been excluded from
this study [43].
Brieﬂy, we deparafﬁnized sections in xylene and we
rehydrated them through graded alcohol, then we used
a Novolink polymer detection system (RE7150-K, Le-
ica, TN) as recommended in the instruction manual.
The slides were incubated with the primary antibody
against Aurora A at 1:50 or pVHL at 1:100 overnight
in a humidity tray. On the one hand, a positive control
was included in each batch: for Aurora A antibody, a
slid of colorectal carcinoma known to overexpress the
autologous antigen and for pVHL antibody, a slid of
healthy kidney which normally expresses this protein
were used (Figs 1A, C). On the other hand, a negative
control was performed by omitting the primary anti-
body and as expected, it did not produce any visible
background staining (Figs 1B, D).
The evaluation used for intensity of staining and sub-
cellular localization was performed in a blinded man-
ner. The intensity of staining was scored as absent (=
0), weak (= 1), moderate (= 2), or strong (= 3) (Figs 2
and 3).
2.4. Statistical analysis
The analysis of the results involving the expression
of both proteins together with the various histological
and clinical parameters were realized, using the chi-
square performed with the program Statistical Pack-
age for Social Sciences (SPSS 13.0). We considered
that results were statistically signiﬁcant when p values
were < 0.05, asterisks (∗) indicates p < 0.05 and (∗∗)
indicates p < 0.01.
3. Results
In the 79 studied samples forAuroraA in tumoral tis-
sue, 35 contain a non tumoral one. Only 36 malignant
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Table 2
Aurora A and pVHL intensity and location in different tissues
Aurora A pVHL
Intensity Non malignant Malignant Non malignant Malignant
tissue tissue tissue tissue
0 25 36 0 0
1 7 9 2 6
2 3 7 8 17
3 0 27 12 13
Location
Cytoplasmic 3 36 20 26
Nuclear and cytoplasmic 7 4 2 10
Nuclear 0 3 0 0
A B
C D
E F
Fig. 1. Aurora A immunostaining in human tissue (x400). Brown color indicates antibody binding and intensity of staining. A, B, C and D:
Immunostaining of malignant kidney tissue: (A): 0 negative staining, (B):+ 1 weak positive staining, (C):+ 2 moderate positive staining, (D):+
3 strong positive staining. E and F: Immunostaining of colorectal carcinoma (x400): (E): with anti-Aurora A antibody: positive control, (F): with-
out anti-AuroraA antibody: ne´gative control. (Colours are visible in the online version of the article; http://dx.doi.org/10.3233/DMA-2012-00942)
tissues were evaluated for pVHL expression, 22 among
them contain a non tumoral tissue.
Using the speciﬁc antibody to the Aurora A kinase,
the expression of these proteins is investigated by im-
munohistochemistry on kidney tissue. Usually, Aurora
A is absent in non- mitotic normal cells, its expression
takes place only during mitosis. When it is expressed
in non-mitotic cells the oncoprotein is considered to
be overexpressed. Accordingly, Aurora A is overex-
pressed in 43 (54.5%) of 79 kidney malignant tissues
and in 10 (26.5%) of 35 non-malignant adjacent tis-
sues. The modiﬁcation of protein expression between
the non-malignant tissue and the malignant one is sup-
ported by signiﬁcant p value 0.01 (Table 2). This ex-
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A B
C
D E
Fig. 2. pVHL protein immunostaining in human tissue (x400). Brown color indicates antibody binding and intensity of staining. A, B and C:
Immunostaining of malignant kidney tissue (x400): (A):+ 1 weak positive staining, (B): + 2 moderate positive staining, (C):+ 3 strong positive
staining. D and E: Immunostaining of healthy kidney tissue (x400): (D): with anti-pVHL antibody: positive control, (E): without anti-pVHL
antibody: ne´gative control. (Colours are visible in the online version of the article; http://dx.doi.org/10.3233/DMA-2012-00942)
pression has been classiﬁed into four levels: 0, 1, 2 and
3; the level 0 corresponding to the absence of the pro-
tein expression, level 1 corresponding to weak expres-
sion, the level 2 corresponding to moderate expression
and the level 3 corresponding to strong expression.
In non-malignant tissue, when Aurora A is overex-
pressed, it does not reach the level 3 of expression in
the tissue. On the other side, 62.8% of malignant tis-
sue expressingAuroraA display high intensity labeling
27/43 at level 3. This difference in high level expres-
sion between malignant and normal adjacent tissue is
signiﬁcant with p = 0.0003∗∗ (Table 2).
When Aurora-A is overexpressed we record the lo-
cation of the protein. In malignant tissue Aurora A
is 83.7% (36) cytoplasmic, 9.3% (4) both nuclear and
cytoplasmic and 7% (3) with only nuclear localization.
In adjacent non-malignant tissue the distribution of the
Aurora A protein is as follows: 30% (3) cytoplasmic
and 70% (7) both nuclear and cytoplasmic. This differ-
ence in location between the non-tumor tissue and tu-
mor one is supported by a signiﬁcant p-value of 0.001∗∗
(Table 2) with a great excess of cytoplasmic location in
tumor tissue.
The expression of Aurora A kinase in tumor tissue
is correlated with the Fuhrman grade with p value of
0.003∗ (Table 3). The expression of Aurora A kinase
in tumor tissue is also correlated with the TNM Classi-
ﬁcation of Malignant Tumours p = 0.008∗∗ (Table 3).
Using autologous antibody, the tumor suppressor
protein pVHL expression is also investigated by IHC
in 36 biopsies. In both neighboring healthy tissue and
tumoral tissues, the pVHL is always expressed how-
ever with some differences in the level and location.
In malignant kidney tissue 16.7% (6) display a weak
intensity, 47.2% (17) intermediate intensity and 36.1%
(13) show a high one. Contrariwise, in non-malignant
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Table 3
Aurora A and pVHL expression with grade and stage
Fuhrman grade
Aurora A intensity I II III IV p = 0.003
0 14 11 9 2
1 5 1 2 1
2 1 5 1 0
3 7 18 2 0
TNM stage
Aurora A intensity T1 T2 T3 p = 0.008
0 15 12 8
1 6 1 2
2 1 0 6
3 15 7 4
Unknown 2
Fuhrman grade
pVHL intensity I II III IV p = 0.054
1 2 3 1 0
2 6 7 1 3
3 3 4 6 0
TNM stage
pVHL intensity T1 T2 T3 p = 0.026
1 2 1 3
2 5 3 9
3 5 6 1
Unknown 1
tissue distribution is as following: 9.1% (2) with low
intensity, 36.4% (8) with moderate intensity and 54.5%
(12) with strong intensity. The difference in protein
expression between adjacent healthy and tumor kidney
tissues is supported by a p value equal to 0.01 (Table 2).
The Von Hippel Lindau protein exhibits a difference
in location between tumor tissue and healthy adjacent
tissue. Indeed in the tumor tissue, this expression is
often observed at a cytoplasmic level 72.2% (26 of 36),
whereas in healthy adjacent tissue this expression is
mainly 90.9% (20 of 22) cytoplasmic. The difference
between the two tissues is not signiﬁcant (Table 2).
However, it seems that pVHL is also expressed at a
nuclear level along with cytoplasmic location in 27%
of tumor tissues whereas only 10% of healthy tissues
display such expression proﬁle.
The expression of pVHL in tumoral tissue according
to the grade of Furman is described in Table 3. This
expression seems to be similar for the different grades.
The decrease of pVHL protein expression in tumor tis-
sue is correlated with the renal capsule rupture (p value
= 0.027∗) as seen in Table 3. It’s also correlated with
the advancedT3 stage according to TNMClassiﬁcation
p = 0.002∗ (Table 3).
The expression of Aurora A and pVHL does not
signiﬁcantly vary according to age, sex and tumor size.
Considering bothmarkers, the tumor suppressor pro-
tein pVHL strong expression associated to a weak ex-
pression of the oncoprotein Aurora A could be regard-
ed as the best prognosis proﬁle and is indeed shown to
be the most frequent in T1 stage. On the contrary, the
over expression of Aura A and pVHL decrease could
be considered as bad prognosis criteria. According to
TNM classiﬁcation, we found that such tumor proﬁles
are frequent in T3 stage. The two kinds of opposite tu-
mor proﬁles display signiﬁcant distribution difference
according to stages with p value of 0.024∗.
4. Discussion
In this study, evidence has been provided for an over-
expression of the oncoprotein Aurora A kinase in tu-
moral kidney cancer tissue, and thus conﬁrming the
previous studies [10–12].
When it was available, we also interestingly noted an
overexpression of the protein in normal adjacent tissue
up to 26.5%, suggesting that this could be an early event
in tumor genesis [11,44].
Our comparative study of the expression of this pro-
tein between tumor and healthy adjacent tissue pin-
point the change of expression in the progression from
the healthy to tumor status and in agreement with the
description of the kinase as being an oncoprotein.
The strong expression of the Aurora A protein level
qualiﬁed by an expression equal to 3, is obvious in
more than the half of the analyzed tumoral tissues,
while in the healthy tissue such expression level is never
reached; which is consistent with the known role of this
protein.
Protein kinase Aurora A expression is predominant-
ly cytoplasmic, which is in agreement with previous
studies [6–8,44]. While in normal tissue, such expres-
sion was mainly both nuclear and cytoplasmic. This
difference in protein location needs to be better inves-
tigated and explained according to its functions and to
its altered structure and/or dysregulation in tumor cells.
The pVHL protein expression was positive in 100%
of the studied tissues: tumor as well as adjacent healthy
tissue, which is in accordancewith the studies done [40,
41,45]. An apparent decrease was recorded in the ex-
pression level of the protein pVHL from healthy to ma-
lignant tissues which is in agreement with the main
function of the protein as a tumor suppressor and with
a previous study of Horng 2003 [40].
Lin 2008, Horng 2003 and Corless 1997 [40,41,45]
found that the expression of the pVHL protein is cy-
toplasmic in 100% of the studied tissues, while in our
work, the staining was chieﬂy cytoplasmic in addition
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to mixed nuclear and cytoplasmic staining. The an-
tibody used in our work, recognizes isoform1 (major
form) and isoform2 of pVHL. The major form is both
cytoplasmic and nuclear [46]. In their respective work,
Lin 2008, Horng 2003 and Corless 1997 [40,41,45]
used antibodies expecting to bind all isoforms and have
recorded only the cytoplasmic presence of the protein.
Our work is in agreement with that of scharmal
2003 [39], and brings to light, for the ﬁrst time, a
link between pVHL protein expression and the grade
of Furhman, TNM classiﬁcation and the renal capsule
rupture, for which statistically signiﬁcant associations
exist.
We suggest that the pVHL protein strong expression
protects against high grade and stage, but since we have
no indication about endogenous VHL gene mutations
nor concerning their effects on VHL protein stability,
this remains a mere supposition. There were a statisti-
cally signiﬁcant association between Aurora A protein
overexpression with the high grade of Furhman [11]
and high stage TNM classiﬁcation.
Indeed the pVHL protein staining is uniform while
the Aurora A protein’s is not. In healthy tissue, the
pVHL protein expression is ubiquitous, whereas the
Aurora A expression takes place only when the cell is
in division, which may partly explain the heterogene-
ity of expression in malignant tissue. Altogether, the
expression levels of the oncoprotein Aurora A and tu-
mor suppressor pVHL correlate in an opposite man-
ner and one has to better investigate to which extent
a high level of Aurora A expression associated to a
reduction in pVHL expression could be considered as
a molecular signature of a high TNM stage and of a
bad prognosis. Considering, Aurora A /pVHL inter-
action [47,48], it could be assumed that the decrease
of pVHL could lead or at least participate to Aurora A
overexpression [18]. Based on such results and on the
observations of the present paper, it could be proposed
that absence of Aurora A protein associated to a strong
expression of pVHL in clear cells kidney carcinoma are
of good prognosis for the disease.
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